Eflornithine
Brand names: Vaniqa
Eflornithine is a topical cream used to reduce unwanted facial hirsutism in women.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It irreversibly inhibits ornithine decarboxylase in the hair follicle, slowing the rate of hair growth rather than removing existing hair.
Prescribing in practice
- It controls rather than cures hirsutism; growth returns towards baseline after stopping, and treatment should be discontinued if no improvement is seen after a reasonable trial.
- It is for facial application only and existing hair-removal methods may need to be continued alongside it.
- Transient stinging, burning or acne-like eruptions at the application site are common and usually mild.
Monitoring
No laboratory monitoring is needed; review for clinical benefit after several weeks and for tolerability of local effects.
Counselling the patient
- Effect is gradual and may take several weeks to become apparent.
- Continue your usual hair-removal routine as the cream slows but does not remove hair.
- Avoid getting the cream in the eyes or on broken skin and wash hands after applying.
Evidence & guidelines
Topical eflornithine is an established adjunct for facial hirsutism, supported by randomised controlled trial data demonstrating reduced hair growth versus vehicle.
Reference: NICE TA61; BAD; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD